Targeting the arrhythmogenic substrate in atrial fibrillation: Focus on structural remodeling

Current Drug Targets

Volumn 12, Issue 2, 2011, Pages 263-286

  Raschi, Emanuel ^a   Boriani, Giuseppe ^b   de Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atrial fibrillation; Fibrosis; Inflammation; Oxidative stress; Structural remodeling; Upstream therapy

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; ACETYLCYSTEINE; ALDOSTERONE ANTAGONIST; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOSIMENDAN; MICRORNA; PIRFENIDONE; POLYUNSATURATED FATTY ACID; PROBUCOL; SUCCINOBUCOL; TEPRENONE; TRICHOSTATIN A;

BRADYCARDIA; DRUG TARGETING; ELECTROLYTE DISTURBANCE; EXTRACELLULAR MATRIX; FIBROSIS; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HUMAN; HYPERTHERMIA; INFLAMMATION; MUSCLE DISEASE; MYOFIBROBLAST; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; REVIEW; TORSADE DES POINTES; ANIMAL; ARTICLE; DRUG EFFECT; HEART ATRIUM; HEART FAILURE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; ATRIAL FIBRILLATION; HEART ATRIA; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; MYOFIBROBLASTS;

EID: 79955657985     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011794182728     Document Type: Review

References (408)

1. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008; 92: 17-40, ix.
2. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 2009; 27: 13-24, vii.
3. Lip GY, Kakar P, Watson T. Atrial fibrillation--the growing epidemic. Heart 2007; 93: 542-43.
4. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042-46.
5. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003; 108: 711-16.
6. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-22.
7. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-73.
8. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-41.
9. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-61.
10. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
11. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-25.
12. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.
13. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534-39.
14. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4: 369-82.
15. Chen LY, Shen WK. Epidemiology of atrial fibrillation: a current perspective. Heart Rhythm 2007; 4: S1-S6.
16. Soliman EZ, Alonso A, Goff DC, Jr. Atrial fibrillation and ethnicity: the known, the unknown and the paradox. Future Cardiol 2009; 5: 547-56.
17. Khoo CW, Lip GY. Burden of atrial fibrillation. Curr Med Res Opin 2009; 25: 1261-63.
18. Boriani G, Diemberger I, Martignani C, Biffi M, Branzi A. The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems. Eur Heart J 2006; 27: 893-94.
19. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90: 286-92.
20. Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006; 9: 348-56.
21. Kim MH, Klingman D, Lin J, Pathak P, Battleman DS. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann Pharmacother 2009; 43: 840-848.
22. Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008; 10: 403-11.
23. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004; 147: 121-26.
24. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-88.
25. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; 1: 526-29.
26. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561-64.
27. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-84.
28. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
29. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 2007; 49: 986-92.
30. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-844.
31. Go O, Rosendorff C. Hypertension and atrial fibrillation. Curr Cardiol Rep 2009; 11: 430-435.
32. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009; 119: 2516-25.
33. Roy D, Talajic M, Dubuc M, et al. Atrial fibrillation and congestive heart failure. Curr Opin Cardiol 2009; 24: 29-34.
34. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationexecutive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006; 27: 1979-2030.
35. Schoonderwoerd BA, Smit MD, Pen L, van Gelder I. New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'. Europace 2008; 10: 668-73.
36. Korantzopoulos P, Liu T, Milionis HJ, Li G, Goudevenos JA. 'Lone' atrial fibrillation: hunting for the underlying causes and links. Int J Cardiol 2009; 131: 180-185.
37. Kozlowski D, Budrejko S, Lip GY, et al. Lone Atrial Fibrillation-What Do We Know? Heart 2009.
38. Initial National Priorities for Comparative Effectiveness Research. List of Priorities. Institute of Medicine of the National Academies. Available at: http://www.ion.edu [Accessed Dec 2, 2010].
39. Nattel S, Allessie M, Haissaguerre M. Spotlight on atrial fibrillation-the 'complete arrhythmia'. Cardiovasc Res 2002; 54: 197-203.
40. Nattel S, Li D, Yue L. Basic mechanisms of atrial fibrillation--very new insights into very old ideas. Annu Rev Physiol 2000; 62: 51-77.
41. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res 2002; 54: 347-60.
42. Page RL, Roden DM. Drug therapy for atrial fibrillation: where do we go from here? Nat Rev Drug Discov 2005; 4: 899-910.
43. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009; 119: 606-18.
44. Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 2004; 64: 2741-62.
45. Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007; 370: 604-18.
46. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 2009; 30: 2969-77c.
47. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
48. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 2008; 10: 647-65.
49. Ehrlich JR, Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs 2009; 69: 757-74.
50. Burashnikov A, Antzelevitch C. New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol 2010; 7: 139-48.
51. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010; 375: 1212-23.
52. Patel C, Yan GX, Kowey PR. Dronedarone. Circulation 2009; 120: 636-44.
53. Ehrlich JR, Biliczki P, Hohnloser SH, Nattel S. Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol 2008; 51: 787-92.
54. McBride BF. The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation. J Clin Pharmacol 2009; 49: 258-67.
55. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002; 415: 219-26.
56. Dorian P. The future of atrial fibrillation therapy. J Cardiovasc Electrophysiol 2006; 17 Suppl 2: S11-S16.
57. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006; 5: 1034-49.
58. Wettwer E, Christ T, Dobrev D, Ravens U. Novel anti-arrhythmic agents for the treatment of atrial fibrillation. Curr Opin Pharmacol 2007; 7: 214-18.
59. Naccarelli GV, Wolbrette DL, Samii S, et al. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther 2007; 5: 707-14.
60. Singh B. Atrial fibrillation: from ion channels to bedside treatment options. J Electrocardiol 2009; 42: 660-670.
61. Ravens U. Antiarrhythmic therapy in atrial fibrillation. Pharmacol Ther 2010; 128: 129-45.
62. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-246.
63. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215-62.
64. Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008; 51: 1-11.
65. Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 2002; 106: 2854-58.
66. Krishnamoorthy S, Lim SH, Lip GY. Assessment of endothelial (dys)function in atrial fibrillation. Ann Med 2009; 41: 576-90.
67. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009; 373: 155-66.
68. Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009; 157: 243-52.
69. Nattel S, Maguy A, Le BS, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 2007; 87: 425-56.
70. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1: 62-73.
71. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
72. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 2005; 13: 181-93.
73. Corradi D, Callegari S, Maestri R, Benussi S, Alfieri O. Structural remodeling in atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008; 5: 782-96.
74. Ausma J, Wijffels M, Thone F, et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997; 96: 3157-63.
75. Everett TH, Li H, Mangrum JM, et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 2000; 102: 1454-60.
76. Ausma J, van D, V, Lenders MH, et al. Reverse structural and gapjunctional remodeling after prolonged atrial fibrillation in the goat. Circulation 2003; 107: 2051-58.
77. Sanders P, Morton JB, Kistler PM, et al. Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy. Circulation 2003; 108: 1976-84.
78. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802-9.
79. Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol 2010; 48: 461-67.
80. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 2003; 9: RA225-RA229.
81. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-92.
82. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27: 136-49.
83. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-28.
84. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007; 115: 135-43.
85. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008; 52: 306-13.
86. Burstein B, Nattel S. Atrial structural remodeling as an antiarrhythmic target. J Cardiovasc Pharmacol 2008; 52: 4-10.
87. Goette A, Lendeckel U. Nonchannel drug targets in atrial fibrillation. Pharmacol Ther 2004; 102: 17-36.
88. Lozano HF, Conde CA, Florin T, Lamas GA. Treatment and prevention of atrial fibrillation with non-antiarrhythmic pharmacologic therapy. Heart Rhythm 2005; 2: 1000-1007.
89. Goette A, Bukowska A, Lendeckel U. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). Curr Opin Pharmacol 2007; 7: 219-24.
90. Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18: 1222-28.
91. Murray KT, Mace LC, Yang Z. Nonantiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm 2007; 4: S88-S90.
92. Dorian P, Singh BN. Upstream therapies to prevent atrial fibrillation. Eur Heart J Suppl 2008; 10: H11-H31.
93. Smit MD, van G, I. Upstream therapy of atrial fibrillation. Expert Rev Cardiovasc Ther 2009; 7: 763-78.
94. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999; 100: 87-95.
95. Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP. Patterns of myocardial fibrosis. J Mol Cell Cardiol 1989; 21 (Suppl 5): 121-31.
96. Silver MA, Pick R, Brilla CG, et al. Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc Res 1990; 24: 741-47.
97. Nishida K, Michael G, Dobrev D, Nattel S. Animal models for atrial fibrillation: clinical insights and scientific opportunities. Europace 2010; 12: 160-72.
98. Nattel S, Shiroshita-Takeshita A, Brundel BJ, Rivard L. Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis 2005; 48: 9-28.
99. Nakajima H, Nakajima HO, Salcher O, et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res 2000; 86: 571-79.
100. Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacinginduced congestive heart failure. Cardiovasc Res 2004; 63: 236-44.
101. Chaldoupi SM, Loh P, Hauer RN, de Bakker JM, van Rijen HV. The role of connexin40 in atrial fibrillation. Cardiovasc Res 2009; 84: 15-23.
102. Dhein S, Hagen A, Jozwiak J, et al. Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides. Naunyn Schmiedebergs Arch Pharmacol 2010; 381: 221-34.
103. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
104. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118: 10-24.
105. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007; 74: 184-95.
106. Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 2007; 74: 207-12.
107. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf) 2009; 195: 321-38.
108. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000; 32: 1805-19.
109. Adam O, Lavall D, Theobald K, et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol 2010; 55: 469-80.
110. Shi-wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15: 2707-19.
111. Horstmeyer A, Licht C, Scherr G, Eckes B, Krieg T. Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1. FEBS J 2005; 272: 6297-309.
112. Shi-wen X, Stanton LA, Kennedy L, et al. CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J Biol Chem 2006; 281: 10715-26.
113. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 2006; 111: 508-31.
114. Burstein B, Libby E, Calderone A, Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for plateletderived growth factor in atrial-ventricular remodeling differences. Circulation 2008; 117: 1630-1641.
115. Schellings MW, Vanhoutte D, van Almen GC, et al. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis. Hypertension 2010; 55: 249-56.
116. Frangogiannis NG. Syndecan-1: a critical mediator in cardiac fibrosis. Hypertension 2010; 55: 233-35.
117. Dschietzig T, Bartsch C, Baumann G, Stangl K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther 2006; 112: 38-56.
118. Samuel CS, Du XJ, Bathgate RA, Summers RJ. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol Ther 2006; 112: 529-52.
119. Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004; 145: 4125-33.
120. Samuel CS. Relaxin: antifibrotic properties and effects in models of disease. Clin Med Res 2005; 3: 241-49.
121. Du XJ, Xu Q, Lekgabe E, et al. Reversal of cardiac fibrosis and related dysfunction by relaxin. Ann N Y Acad Sci 2009; 1160: 278-84.
122. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077-91.
123. Kagitani S, Ueno H, Hirade S, et al. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 2004; 22: 1007-15.
124. Martin J, Kelly DJ, Mifsud SA, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 2005; 65: 694-701.
125. Frustaci A, Caldarulo M, Buffon A, et al. Cardiac biopsy in patients with "primary" atrial fibrillation. Histologic evidence of occult myocardial diseases. Chest 1991; 100: 303-6.
126. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
127. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 96: 3542-48.
128. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-91.
129. Aviles RJ, Martin DO, Pperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-10.
130. Boos CJ, Lip GY. Inflammation and atrial fibrillation: cause or effect? Heart 2008; 94: 133-34.
131. Kallergis EM, Manios EG, Kanoupakis EM, et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 2008; 94: 200-204.
132. Patel P, Dokainish H, Tsai P, Lakkis N. Update on the Association of Inflammation and Atrial Fibrillation. J Cardiovasc Electrophysiol 2010; 21: 1064-70.
133. Rudolph V, Andrie RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16: 470-474.
134. Marcus GM, Smith LM, Ordovas K, et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 2010; 7: 149-54.
135. Dixit S. Atrial fibrillation and inflammation: quest for the missing link in the etiopathogenesis of AF. Heart Rhythm 2010; 7: 155-56.
136. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104: 174-80.
137. Neuman RB, Bloom HL, Shukrullah I, et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 2007; 53: 1652-57.
138. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89: E32-E38.
139. Carnes CA, Janssen PM, Ruehr ML, et al. Atrial glutathione content, calcium current, and contractility. J Biol Chem 2007; 282: 28063-73.
140. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844.
141. Dudley SC, Jr., Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 2005; 112: 1266-73.
142. Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005; 97: 900-907.
143. Adam O, Frost G, Custodis F, et al. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 2007; 50: 359-67.
144. Kim YM, Guzik TJ, Zhang YH, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005; 97: 629-36.
145. Rocken C, Peters B, Juenemann G, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002; 106: 2091-97.
146. Leone O, Boriani G, Chiappini B, et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J 2004; 25: 1237-41.
147. Schubert D, Behl C, Lesley R, et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci U S A 1995; 92: 1989-93.
148. Gyorke S, Carnes C. Dysregulated sarcoplasmic reticulum calcium release: potential pharmacological target in cardiac disease. Pharmacol Ther 2008; 119: 340-354.
149. Ruffolo RR, Jr., Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 1998; 32 Suppl 1: S22-S30.
150. Li PF, Dietz R, von HR. Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor-beta1 in cardiac fibroblasts. FEBS Lett 1999; 448: 206-10.
151. Fukuda K, Davies SS, Nakajima T, et al. Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. Circ Res 2005; 97: 1262-69.
152. Caouette D, Dongmo C, Berube J, Fournier D, Daleau P. Hydrogen peroxide modulates the Kv1.5 channel expressed in a mammalian cell line. Naunyn Schmiedebergs Arch Pharmacol 2003; 368: 479-86.
153. Shimano M, Shibata R, Inden Y, et al. Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart Rhythm 2009; 6: 935-40.
154. Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438-44.
155. Liu T, Li G. Antioxidant interventions as novel preventive strategies for postoperative atrial fibrillation. Int J Cardiol 2009.
156. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005; 45: 657-87.
157. Sorrell JM, Caplan AI. Fibroblasts-a diverse population at the center of it all. Int Rev Cell Mol Biol 2009; 276: 161-214.
158. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997; 151: 317-22.
159. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer 2004; 108: 173-80.
160. MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res 2000; 46: 257-63.
161. Gupta V, Grande-Allen KJ. Effects of static and cyclic loading in regulating extracellular matrix synthesis by cardiovascular cells. Cardiovasc Res 2006; 72: 375-83.
162. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117: 1538-49.
163. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7: 827-40.
164. Baudino TA, Carver W, Giles W, Borg TK. Cardiac fibroblasts: friend or foe? Am J Physiol Heart Circ Physiol 2006; 291: H1015-H1026.
165. Kamkin A, Kiseleva I, Lozinsky I, Scholz H. Electrical interaction of mechanosensitive fibroblasts and myocytes in the heart. Basic Res Cardiol 2005; 100: 337-45.
166. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349-63.
167. Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971; 27: 549-50.
168. Aikawa E, Whittaker P, Farber M, et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation 2006; 113: 1344-52.
169. Lijnen P, Petrov V. Transforming growth factor-beta 1-induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. Methods Find Exp Clin Pharmacol 2002; 24: 333-44.
170. Hinz B. The myofibroblast: paradigm for a mechanically active cell. J Biomech 2010; 43: 146-55.
171. Yan-Hong F, Hui D, Qing P, et al. Effects of Arginine Vasopressin on Differentiation of Cardiac Fibroblasts into Myofibroblasts. J Cardiovasc Pharmacol 2010; 55: 488-95.
172. Burstein B, Qi XY, Yeh YH, Calderone A, Nattel S. Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc Res 2007; 76: 442-52.
173. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res 2009; 105: 1164-76.
174. Kakkar R, Lee RT. Intramyocardial fibroblast myocyte communication. Circ Res 2010; 106: 47-57.
175. Camelliti P, Green CR, LeGrice I, Kohl P. Fibroblast network in rabbit sinoatrial node: structural and functional identification of homogeneous and heterogeneous cell coupling. Circ Res 2004; 94: 828-35.
176. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 2005; 65: 40-51.
177. Kohl P, Camelliti P, Burton FL, Smith GL. Electrical coupling of fibroblasts and myocytes: relevance for cardiac propagation. J Electrocardiol 2005; 38: 45-50.
178. Miragoli M, Gaudesius G, Rohr S. Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circ Res 2006; 98: 801-10.
179. Jacquemet V, Henriquez CS. Loading effect of fibroblast-myocyte coupling on resting potential, impulse propagation, and repolarization: insights from a microstructure model. Am J Physiol Heart Circ Physiol 2008; 294: H2040-H2052.
180. Rohr S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias? Heart Rhythm 2009; 6: 848-56.
181. Xie Y, Garfinkel A, Camelliti P, et al. Effects of fibroblastmyocyte coupling on cardiac conduction and vulnerability to reentry: A computational study. Heart Rhythm 2009; 6: 1641-49.
182. Maleckar MM, Greenstein JL, Giles WR, Trayanova NA. Electrotonic coupling between human atrial myocytes and fibroblasts alters myocyte excitability and repolarization. Biophys J 2009; 97: 2179-90.
183. Lin YK, Chen YJ, Chen SA. Potential atrial arrhythmogenicity of adipocytes: Implications for the genesis of atrial fibrillation. Med Hypotheses 2010; 74: 1026-9.
184. Liao CH, Akazawa H, Tamagawa M, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 2010; 120: 242-53.
185. Ross RS. Molecular and mechanical synergy: cross-talk between integrins and growth factor receptors. Cardiovasc Res 2004; 63: 381-90.
186. Manso AM, Elsherif L, Kang SM, Ross RS. Integrins, membranetype matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. Cardiovasc Res 2006; 69: 574-84.
187. Manso AM, Kang SM, Ross RS. Integrins, focal adhesions, and cardiac fibroblasts. J Investig Med 2009; 57: 856-60.
188. Bornstein P. Cell-matrix interactions: the view from the outside. Methods Cell Biol 2002; 69: 7-11.
189. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14: 608-16.
190. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 2004; 64: 24-31.
191. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-342.
192. Espira L, Czubryt MP. Emerging concepts in cardiac matrix biology. Can J Physiol Pharmacol 2009; 87: 996-1008.
193. Bowers SL, Banerjee I, Baudino TA. The extracellular matrix: at the center of it all. J Mol Cell Cardiol 2010; 48: 474-82.
194. Cardin S, Libby E, Pelletier P, et al. Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ Res 2007; 100: 425-33.
195. Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 2008; 65: 1489-508.
196. Mukherjee R, Herron AR, Lowry AS, et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 2006; 97: 532-37.
197. Nakano Y, Niida S, Dote K, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004; 43: 818-25.
198. Chen CL, Huang SK, Lin JL, et al. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol 2008; 45: 742-53.
199. Moe GW, Laurent G, Doumanovskaia L, et al. Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure. J Card Fail 2008; 14: 768-76.
200. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009; 123: 255-78.
201. Kizana E, Ginn SL, Allen DG, Ross DL, Alexander IE. Fibroblasts can be genetically modified to produce excitable cells capable of electrical coupling. Circulation 2005; 111: 394-98.
202. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008; 5: 30-41.
203. Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol 2010; 381: 1-13.
204. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19.
205. Freestone B, Beevers DG, Lip GY. The renin-angiotensinaldosterone system in atrial fibrillation: a new therapeutic target? J Hum Hypertens 2004; 18: 461-65.
206. Boos CJ, Lip GY. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 2005; 19: 855-59.
207. Choudhury A, Varughese GI, Lip GY. Targeting the reninangiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy? Expert Opin Pharmacother 2005; 6: 2193-207.
208. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152: 217-22.
209. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27: 512-18.
210. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 2006; 46: 21-28.
211. Patlolla V, sheikh-Ali AA, Al-Ahmad AM. The renin-angiotensin system: a therapeutic target in atrial fibrillation. Pacing Clin Electrophysiol 2006; 29: 1006-12.
212. Novo G, Guttilla D, Fazio G, Cooper D, Novo S. The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol 2008; 66: 345-51.
213. Barra S, Silvestri N, Vitagliano G, Madrid A, Gaeta G. Angiotensin II receptor blockers in the prevention of atrial fibrillation. Expert Opin Pharmacother 2009; 10: 1395-411.
214. Makkar KM, Sanoski CA, Spinler SA. Role of angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 2009; 29: 31-48.
215. Tsai CT, Lai LP, Lin JL, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004; 109: 1640-1646.
216. Goette A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation. Cardiovasc Res 2002; 54: 247-58.
217. Goette A, Arndt M, Rocken C, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678-81.
218. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953-70.
219. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-C97.
220. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-77.
221. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002; 91: 1103-13.
222. Dostal DE, Hunt RA, Kule CE, et al. Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. J Mol Cell Cardiol 1997; 29: 2893-902.
223. Marrero MB, Schieffer B, Li B, et al. Role of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II-and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 1997; 272: 24684-90.
224. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 2007; 73: 463-69.
225. Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin IIinduced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007; 292: H736-H742.
226. Mercure C, Yogi A, Callera GE, et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008; 103: 1319-26.
227. Iwata M, Cowling RT, Gurantz D, et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 2005; 289: H2356-H2363.
228. Paul M, Poyan MA, Kreutz R. Physiology of local reninangiotensin systems. Physiol Rev 2006; 86: 747-803.
229. Kumar R, Singh VP, Baker KM. The intracellular reninangiotensin system: a new paradigm. Trends Endocrinol Metab 2007; 18: 208-14.
230. Kumar R, Singh VP, Baker KM. The intracellular reninangiotensin system: implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens 2008; 17: 168-73.
231. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucoseinduced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 2007; 293: H939-H948.
232. Singh VP, Baker KM, Kumar R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol 2008; 294: H1675-H1684.
233. Kumar R, Boim MA. Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens 2009; 18: 33-39.
234. Garg S, Narula J, Marelli C, Cesario D. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias. Am J Cardiol 2006; 97: 921-25.
235. Levy S. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications. Nat Clin Pract Cardiovasc Med 2006; 3: 220-225.
236. Iravanian S, Dudley SC, Jr. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 2008; 5: S12-S17.
237. Serra JL, Bendersky M. Atrial fibrillation and renin-angiotensin system. Ther Adv Cardiovasc Dis 2008; 2: 215-23.
238. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997; 96: 1686-95.
239. Carver W, Nagpal ML, Nachtigal M, Borg TK, Terracio L. Collagen expression in mechanically stimulated cardiac fibroblasts. Circ Res 1991; 69: 116-22.
240. Riser BL, Cortes PF, Heilig CF, et al. Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol 1996; 148: 1915-23.
241. Zou YF, Akazawa HF, Qin YF, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Cell Biol 2004; 6: 499-506.
242. Blayney LM, Lai FA. Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol Ther 2009; 123: 151-77.
243. Delpon E, Caballero R, Gomez R, Nunez L, Tamargo J. Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends Pharmacol Sci 2005; 26: 155-61.
244. Moreno I, Caballero R, Gonzalez T, et al. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther 2003; 304: 862-73.
245. Nakashima HF, Kumagai KF, Urata HF, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-7.
246. Kumagai KF, Nakashima HF, Urata HF, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-204.
247. Li D, Shinagawa K, Pang L, et al. Effects of angiotensinconverting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-14.
248. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54: 456-61.
249. Cardin S, Li D, Thorin-Trescases N, et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and-independent pathways. Cardiovasc Res 2003; 60: 315-25.
250. Okazaki HF, Minamino TF, Tsukamoto OF, et al. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. Hypertens Res 2006; 29: 277-84.
251. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009; 54: 2023-31.
252. Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152: 78-84.
253. Naccarelli GV, Peacock F. Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation. Vasc Health Risk Manag 2009; 5: 783-91.
254. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-9.
255. Schneider MP, Hua TA, Bohm M, et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a metaanalysis. J Am Coll Cardiol 2010; 55: 2299-307.
256. Zhang YF, Zhang PF, Mu YF, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther 2010; 88: 521-31.
257. Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-17.
258. Lendeckel U, Dobrev D, Goette A. Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. Br J Pharmacol 2010; 159: 1581-3.
259. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
260. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
261. Pitt B, Pitt GS. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation 2007; 115: 2976-82.
262. Lemarie CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86: 673-8.
263. Goette A, Hoffmanns P, Enayati W, et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001; 88: 906-9, A8.
264. Milliez P, Deangelis N, Rucker-Martin C, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005; 26: 2193-9.
265. Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 2006; 17: 534-41.
266. Yang SS, Han W, Zhou HY, et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl) 2008; 121: 38-42.
267. Chun TY, Bloem LJ, Pratt JH. Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology 2003; 144: 1712-7.
268. Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010; 159: 1584-94.
269. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-35.
270. Skott O, Uhrenholt TR, Schjerning J, et al. Rapid actions of aldosterone in vascular health and disease--friend or foe? Pharmacol Ther 2006; 111: 495-507.
271. Gao X, Peng L, Adhikari CM, Lin J, Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007; 13: 170-7.
272. Tsai CT, Chiang FT, Tseng CD, et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010; 55: 758-70.
273. van der HP, Voors AA, van Gilst WH, Bohm M, van Veldhuisen DJ. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006; 71: 443-54.
274. Hadi HA, Mahmeed WA, Suwaidi JA, Ellahham S. Pleiotropic effects of statins in atrial fibrillation patients: the evidence. Vasc Health Risk Manag 2009; 5: 533-51.
275. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Do statins have an antiarrhythmic activity? Cardiovasc Res 2007; 75: 10-20.
276. Tamargo J, Caballero R, Gomez R, et al. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther 2007; 114: 107-26.
277. Adam O, Neuberger HR, Bohm M, Laufs U. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 2008; 118: 1285-93.
278. Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007; 74: 75-84.
279. Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 2004; 64: 507-15.
280. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110: 2313-9.
281. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-11.
282. Wassmann S, Nickenig G. Improvement of Endothelial Function by HMG-CoA Reductase Inhibitors. Drug News Perspect 2002; 15: 85-92.
283. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-5.
284. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 93: e98-103.
285. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-63.
286. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-8.
287. Liu T, Li GP. Statins may prevent postoperative atrial fibrillation through autonomic modulation. Am J Cardiol 2006; 97: 1266.
288. Yagi S, Akaike M, Aihara K, et al. Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension 2010; 55: 918-23.
289. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
290. Vaquero M, Caballero R, Gomez R, et al. Effects of atorvastatin and simvastatin on atrial plateau currents. J Mol Cell Cardiol 2007; 42: 931-45.
291. Lee TM, Lin MS, Chou TF, Tsai CH, Chang NC. Effect of pravastatin on left ventricular mass by activation of myocardial K ATP channels in hypercholesterolemic rabbits. Atherosclerosis 2004; 176: 273-8.
292. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 2006; 316: 1098-106.
293. Tsai CT, Lai LP, Kuo KT, et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008; 117: 344-55.
294. Shyu KG, Wang BW, Chen WJ, Kuan P, Hung CR. Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail 2010; 12: 219-26.
295. Amar D, Zhang H, Heerdt PM, et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 2005; 128: 3421-7.
296. Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97: 55-60.
297. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-61.
298. Ozaydin M, Dogan A, Varol E, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007; 107: 117-21.
299. Song YB, On YK, Kim JH, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008; 156: 373-16.
300. Liakopoulos OJ, Choi YH, Kuhn EW, et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg 2009; 138: 678-86.
301. Fauchier L, Pierre B, de LA, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008; 51: 828-35.
302. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and metaanalysis of randomized clinical trials and observational studies. Int J Cardiol 2008; 126: 160-70.
303. Liu T, Li G, Korantzopoulos P, Goudevenos JA. Statins and prevention of atrial fibrillation in patients with heart failure. Int J Cardiol 2009; 135: e83-e84.
304. Hanna IR, Heeke B, Bush H, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3: 881-6.
305. Maggioni AP, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009; 30: 2327-36.
306. Kourliouros A, De SA, Roberts N, et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg 2008; 85: 1515-20.
307. Mithani S, Akbar MS, Johnson DJ, et al. Dose dependent effect of statins on postoperative atrial fibrillation after cardiac surgery among patients treated with beta blockers. J Cardiothorac Surg 2009; 4: 61.
308. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke 2006; 37: 2640-3.
309. Vedre A, Gurm HS, Froehlich JB, et al. Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events
310. Dawe DE, Ariyarajah V, Khadem A. Is there a role for statins in atrial fibrillation? Pacing Clin Electrophysiol 2009; 32: 1063-72.
311. Ninio DM, Murphy KJ, Howe PR, Saint DA. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol 2005; 16: 1189-94.
312. Ueshima H, Stamler J, Elliott P, et al. Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure: INTERMAP study. Hypertension 2007; 50: 313-9.
313. Appel LJ, Miller ER, III, Seidler AJ, Whelton PK. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med 1993; 153: 1429-38.
314. Rasmussen BM, Vessby B, Uusitupa M, et al. Effects of dietary saturated, monounsaturated, and n-3 fatty acids on blood pressure in healthy subjects. Am J Clin Nutr 2006; 83: 221-6.
315. Shimokawa H, Vanhoutte PM. Dietary omega 3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries. Am J Physiol 1989; 256: H968-H973.
316. Yin K, Chu ZM, Beilin LJ. Blood pressure and vascular reactivity changes in spontaneously hypertensive rats fed fish oil. Br J Pharmacol 1991; 102: 991-7.
317. Chu ZM, Yin K, Beilin LJ. Fish oil feeding selectively attenuates contractile responses to noradrenaline and electrical stimulation in the perfused mesenteric resistance vessels of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1992; 19: 177-81.
318. McVeigh GE, Brennan GM, Cohn JN, et al. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1994; 14: 1425-9.
319. McLennan PL, Bridle TM, Abeywardena MY, Charnock JS. Comparative efficacy of n-3 and n-6 polyunsaturated fatty acids in modulating ventricular fibrillation threshold in marmoset monkeys. Am J Clin Nutr 1993; 58: 666-9.
320. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003; 107: 2646-52.
321. Leaf A, Xiao YF, Kang JX, Billman GE. Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids. Pharmacol Ther 2003; 98: 355-77.
322. London B, Albert C, Anderson ME, et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 2007; 116: e320-e335.
323. Li GR, Sun HY, Zhang XH, et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+currents and Na+current in human atrial myocytes. Cardiovasc Res 2009; 81: 286-93.
324. Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 2007; 116: 2101-9.
325. Boland LM, Drzewiecki MM. Polyunsaturated fatty acid modulation of voltage-gated ion channels. Cell Biochem Biophys 2008; 52: 59-84.
326. Xiao YF, Sigg DC, Leaf A. The antiarrhythmic effect of n-3 polyunsaturated fatty acids: modulation of cardiac ion channels as a potential mechanism. J Membr Biol 2005; 206: 141-54.
327. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006; 83: 1505S-19S.
328. Sarrazin JF, Comeau G, Daleau P, et al. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs. J Am Coll Cardiol 2007; 50: 1505-12.
329. Laurent G, Moe G, Hu X, et al. Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model. Cardiovasc Res 2008; 77: 89-97.
330. Ramadeen A, Laurent G, Dos Santos CC, et al. n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. Heart Rhythm 2010; 7: 520-8.
331. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004; 110: 368-73.
332. Calo L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005; 45: 1723-8.
333. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005; 81: 50-4.
334. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Witteman JC. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006; 151: 857-62.
335. Saravanan P, Bridgewater B, West AL, et al. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 2010; 3: 46-53.
336. Heidarsdottir R, Arnar DO, Skuladottir GV, et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 2010; 12: 356-63.
337. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006; 332: 752-60.
338. Leon H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 2008; 337: a2931.
339. Den Ruijter HM, Berecki G, Opthof T, et al. Pro-and antiarrhythmic properties of a diet rich in fish oil. Cardiovasc Res 2007; 73: 316-25.
340. Opthof T, Den Ruijter HM. Omega-3 polyunsaturated fatty acids (PUFAs or fish oils) and atrial fibrillation. Br J Pharmacol 2007; 150: 258-60.
341. Rodrigo R, Cereceda M, Castillo R, et al. Prevention of atrial fibrillation following cardiac surgery: basis for a novel therapeutic strategy based on non-hypoxic myocardial preconditioning. Pharmacol Ther 2008; 118: 104-27.
342. Rodrigo R, Vinay J, Castillo R, et al. Use of vitamins C and E as a prophylactic therapy to prevent postoperative atrial fibrillation. Int J Cardiol 2010; 138: 221-28.
343. Ozaydin M, Peker O, Erdogan D, et al. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. Eur Heart J 2008; 29: 625-31.
344. Rodrigo R, Guichard C, Charles R. Clinical pharmacology and therapeutic use of antioxidant vitamins. Fundam Clin Pharmacol 2007; 21: 111-27.
345. Eslami M, Badkoubeh RS, Mousavi M, et al. Oral ascorbic acid in combination with beta-blockers is more effective than betablockers alone in the prevention of atrial fibrillation after coronary artery bypass grafting. Tex Heart Inst J 2007; 34: 268-74.
346. Umeji K, Umemoto S, Itoh S, et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol Heart Circ Physiol 2006; 291: H2522-H2532.
347. Singla DK, Kaur K, Sharma AK, Dhingra S, Singal PK. Probucol promotes endogenous antioxidant reserve and confers protection against reperfusion injury. Can J Physiol Pharmacol 2007; 85: 439-43.
348. Gong YT, Li WM, Li Y, et al. Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Chin Med J (Engl) 2009; 122: 74-82.
349. Li Y, Sheng L, Li W, et al. Probucol attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in dogs. Biochem Biophys Res Commun 2009; 381: 198-203.
350. Guo J, Massaeli H, Li W, et al. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther 2007; 321: 911-20.
351. Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 1761-68.
352. Liu T, Li G. Probucol and succinobucol in atrial fibrillation: Pros and cons. Int J Cardiol 2010; 144: 285-6.
353. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 2006; 69: 865-75.
354. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25: 1100-1107.
355. Halonen J, Halonen P, Jarvinen O, et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA 2007; 297: 1562-67.
356. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation 2009; 119: 1853-66.
357. Huerta C, Lanes SF, Garcia Rodriguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005; 16: 360-366.
358. van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006; 166: 1016-20.
359. Christiansen CF, Christensen S, Mehnert F, et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, casecontrol study. Arch Intern Med 2009; 169: 1677-83.
360. Liu T, Shehata M, Li G, Wang X. Androgens and atrial fibrillation: Friends or foes? Int J Cardiol 2010; [Epub ahead of print].
361. Kaushik M, Sontineni SP, Hunter C. Cardiovascular disease and androgens: A review. Int J Cardiol 2010; 142: 8-14.
362. Tsuneda T, Yamashita T, Kato T, et al. Deficiency of testosterone associates with the substrate of atrial fibrillation in the rat model. J Cardiovasc Electrophysiol 2009; 20: 1055-60.
363. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart 2004; 90: 473-75.
364. Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999; 17: 851-57.
365. Lau DH, Stiles MK, John B, et al. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol 2007; 117: e86-e87.
366. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007; 25: 731-41.
367. Dandona P, Karne R, Ghanim H, et al. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000; 101: 122-24.
368. El-Sherif N, Turitto G. Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent? Pacing Clin Electrophysiol 2005; 28: 985-90.
369. Kamei M, Morita S, Hayashi Y, Kanmura Y, Kuro M. Carvedilol versus Metoprolol for the prevention of atrial fibrillation after offpump coronary bypass surgery: rationale and design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT). Cardiovasc Drugs Ther 2006; 20: 219-27.
370. Gheorghiade M, Lukas MA. Role of carvedilol in atrial fibrillation: insights from clinical trials. Am J Cardiol 2004; 93: 53B-7B.
371. Katritsis DG, Panagiotakos DB, Karvouni E, et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol 2003; 92: 1116-19.
372. Haghjoo M, Saravi M, Hashemi MJ, et al. Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm 2007; 4: 1170-1174.
373. Acikel S, Bozbas H, Gultekin B, et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int J Cardiol 2008; 126: 108-13.
374. Celik T, Iyisoy A, Jata B, et al. Beta blockers for the prevention of atrial fibrillation after coronary artery bypass surgery: carvedilol versus metoprolol. Int J Cardiol 2009; 135: 393-96.
375. Liu T, Li G, Xu G. Levosimendan may prevent postoperative atrial fibrillation through anti-inflammatory and antioxidant modulation. J Cardiothorac Vasc Anesth 2009; 23: 757-58.
376. De Hert SG, Lorsomradee S, vanden EH, Cromheecke S, Van der Linden PJ. A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction. J Cardiothorac Vasc Anesth 2008; 22: 699-705.
377. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-91.
378. Sovari AA, Morita N, Karagueuzian HS. Apocynin: a potent NADPH oxidase inhibitor for the management of atrial fibrillation. Redox Rep 2008; 13: 242-45.
379. Cavolli R, Kaya K, Aslan A, et al. Does sodium nitroprusside decrease the incidence of atrial fibrillation after myocardial revascularization?: a pilot study. Circulation 2008; 118: 476-81.
380. Lee KW, Everett TH, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006; 114: 1703-12.
381. Liu F, Levin MD, Petrenko NB, et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol 2008; 45: 715-23.
382. Iyer A, Fenning A, Lim J, et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 2010; 159: 1408-17.
383. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004; 27: 982-91.
384. Fliegner D, Westermann D, Riad A, et al. Up-regulation of PPARgamma in myocardial infarction. Eur J Heart Fail 2008; 10: 30-38.
385. Teunissen BE, Smeets PJ, Willemsen PH, et al. Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovasc Res 2007; 75: 519-29.
386. Hao GH, Niu XL, Gao DF, Wei J, Wang NP. Agonists at PPARgamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol 2008; 153: 1409-19.
387. Shimano M, Tsuji Y, Inden Y, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008; 5: 451-59.
388. Liu T, Korantzopoulos P, Li G, Li J. The potential role of thiazolidinediones in atrial fibrillation. Int J Cardiol 2008; 128: 129-30.
389. Anglade MW, Kluger J, White CM, Aberle J, Coleman CI. Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study. Curr Med Res Opin 2007; 23: 2849-55.
390. Korantzopoulos P, Kokkoris S, Kountouris E, et al. Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy. Int J Cardiol 2008; 125: e51-e53.
391. Brundel BJ, Ke L, Dijkhuis AJ, et al. Heat shock proteins as molecular targets for intervention in atrial fibrillation. Cardiovasc Res 2008; 78: 422-28.
392. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
393. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007; 101: 1225-36.
394. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 2008; 79: 562-70.
395. Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat Rev Cardiol 2009; 6: 419-29.
396. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007; 117: 2369-76.
397. Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 2008; 103: 1072-83.
398. Pan ZW, Lu YJ, Yang BF. MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases. Acta Pharmacol Sin 2010; 31: 1-9.
399. Shan H, Zhang Y, Lu Y, et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009; 83: 465-72.
400. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13027-32.
401. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-984.
402. Roy S, Khanna S, Hussain SR, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82: 21-29.
403. Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104: 170-8, 6p.
404. Girmatsion Z, Biliczki P, Bonauer A, et al. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm 2009; 6: 1802-9.
405. Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13: 486-91.
406. Castanotto D, Rossi JJ. The promises and pitfalls of RNAinterference-based therapeutics. Nature 2009; 457: 426-33.
407. Prystowsky EN, Camm J, Lip GY, et al. The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. J Cardiovasc Electrophysiol 2010; 21: 946-58.
408. Anne W, Duytschaever M. Upstream therapy in atrial fibrillation: traveling up the river to find the source. Heart Rhythm 2010; 7: 529-30.